Wafik El-Deiry shared posts on LinkedIn and X: .
“Grateful for opportunity to speak about the Worldwide Innovative Network WIN Consortium in cancer personalized medicine N-of-1 precision oncology basket or disease specific trials, AI algorithms, digital pathology, molecular tumor boards, functional precision medicine and novel omics. DAVA Oncology 3rd Global Thoracic Malignancies Summit.
WIN is pursuing the next generation of precision in cancer care in the way it will be more commonly practiced in the future. We can make this happen earlier by working together to address challenges (drug access, financial toxicity, policies for drug approval, lack of understanding that N-of-1 trials provide early signal of synergies based on personal omics much faster and more efficiently than any other phase 1b/2 trial design, lack of drugs to address important molecular drivers, data standards and access) while demonstrating personalized patient benefit through advanced inclusive trial designs. Innovation, equity, diversity, collaboration and global impact are what WIN is about.
The WIN Consortium welcomes academic institutions, pharmaceutical companies, biotechnology companies, patient advocacy groups, professional societies and foundations who would like to move the field to realize the value of precision cancer therapeutics and prevention for patients.
Interesting talk by Dr. John Heymach about pursuing the goal of cure in lung cancer, neoadjuvant versus adjuvant therapy, monitoring MRD, PD-L1 relationship to metastasis, neoadjuvant better immune response with ICB with lots of emerging evidence.
Dr. David Carbone at Ohio State University speaks about DLL3 in SCLC as an attractive therapeutic target. ADC Rovalpituzumab had low response rate with lots of toxicity. Good target but bad drug for various reasons. Tarlatamab has more than 40% response rate and durable!
Case of Tarlatamab with SCLC with brain mets who received 1 cycle of therapy in 3rd line and has had CR with NED for more than 2 years.
Dr. Barbara Melosky speaks about ADAURA and ctDNA as predictive with lead time of 4.7 months.
MRD = game changer.
Dr. Heymach at MD Anderson Cancer Center speaks about DLL3-directed CAR-T therapy for SCLC.
Says a lot of mutations in SCLC still has a cold TME plus also an inhospitable environment for killing the tumor cells.
Spoke about SCLC clustering in 4 distinct immune profiles including an inflamed subtype that derives some benefit from immunotherapy. DLL3 more in least inflamed SCLC.
Spoke about early clinical data with DLL3 CAR-T.
Dr. Martin Edelman at Fox Chase Cancer Center speaks about Adagrasib and the remarkable results from KRYSTAL1 study.
Dr. Marcelo Negrao at MD Anderson Cancer Center speaks about Olomorasib in KRAS G12C mutated NSCLC. Mentioned that comutations in 1/3 of patients in genes such as Keap1 or CDKN2A there was primary resistance. Also showed data for 39% response even after progression on other G12C inhibitors. Less hepatotoxicity and there is efficacy against brain mets.
Dr. Ravi Salgia speaks about genetic and nongenetic mechanisms for G12C drugs that will be relevant to pan-RAS drugs and degraders. Tolerant persisters are reversible while resistant cells are not. Mechs include other RAS mutations, RAS-Gap, Myc, EGFR, p53, Rb, CDKN2A, and spoke about a zebrafish PDX model that led to combo with carfilzomib.
Dr. Misako Nagasaka speaks about targeting NRG1 fusions with Zenocituzumab (bispecific to Her2 and Her3 that prevents NRG1 binding to Her3).
Dr. David Barbie uses PDX models to test STING agonists in MPM therapy. Precision oncology for ADC’s.
Dr. Anne Chang at Yale Cancer Center speaks about ABBV-706 in solid tumors including SCLC.
Impressive response rate in SCLC and even NEN’s.
Dr. Sawsan Rashdan speaks about treating leptomeningeal disease progression on osimertinib.
I asked about Avastin and also about immune checkpoint blockade with MDM2 amplification in a patient with a Met driven lung cancer with brain mets regarding
1- whether Avastin might interfere with TKI penetration of the tumor and
2- whether immune checkpoint blockade should be avoided due to the MDM2 amplification due to risk of hyperprogression.
The panel chaired by Dr. Edelman at Fox Chase Cancer Center answered that
1- Avastin improves TKI penetration and suggested
2- immune checkpoint blockade as standard of care as there is no data to suggest an issue with MDM2 (lack of data).
Great to meet patient advocate Marcia Horn at the DAVA Oncology 3rd Global Summit on Thoracic Malignancies. Marcia K. Horn is President and CEO of
ICAN, the
International Cancer Advocacy Network.
Great to meet Biljana Namauvic at J&J at the DAVA Oncology 3rd Global Summit on Thoracic Malignancies. We began discussing good opportunities for collaboration with the WIN Consortium.
Biljana Naumovic is the Worldwide Vice President, Global Commercial Strategy, Oncology for the Janssen Pharmaceutical Companies of Johnson & Johnson.
Drs. Ravi Salgia and Patrick Ma gave amazing talks about ALK+ lung cancer at DAVA Oncology 3rd Global Thoracic Malignancies Summit.
Dr. Salgia reviewed evolution of drugs, resistance, improved survival from the days of crizotinib to lorlatinib, and use of drugs in different resistance settings.
Dr. Ma spoke about long term exceptional responses after life-threatening advanced disease. Great hope for patients with the ALK driver.
Great to see Dr. Vinay Jain this morning. Dr. Jain, the CEO of DAVA Oncology is an experienced oncologist who previously founded PER, and other non-profits. He organizes amazing global Oncologic Specialty summits focused on accelerating clinical trials driven by leaders in the field. The mix of academia and industry makes these meetings very special and extremely good and focused learning opportunities.
Dr. Barbara Melosky gives great talk at DAVA Oncology on Dato-DXd analysis in NSCLC, Trop, differences between squamous (does worse) versus adenocarcinoma where patients with Actionable Genomic Alterations (AGA’s) benefit.
Terrific talk by Dr. So Yoon Kim at Yale School of Medicine on MET Exon 14 skipping mutations in NSCLC.
DAVA Oncology 3rd Global Thoracic Malignancies Summit.
Gave my second talk at the DAVA Oncology 3rd Global Thoracic Malignancies Summit this morning before heading to airport to return to Rhode Island. I had 30 slides that I went through in 9 minutes.
Thanks to Dr. Christopher Azzoli for introducing me and Eldeiry lab to Lurbinectedin. Lurbinectedin is an analogue of trabectedin isolated from the Sea Squirt.
It was fun to tell the audience about the Sea Squirt, a bottom dweller that filters the sea water for food, is eaten by many fish and is also a delicacy in some Asian countries. It is rich in alanine and glycine, has a strong sea flavor and some bitterness (I won’t be eating them any time soon). Ma-hoya has a stronger flavor, while Aka-hoya is milder.
My talk was 2 mins over probably due to the detour to discuss the Sea Squirt but I kept their attention. I shared our preclinical data on rescue of radiation pneumonitis and dermatitis by TRAIL pathway agonists. This is an important area for the lung cancer community in addition to therapeutic development. We are looking at rescue of pneumonitis caused by radiation, ICB or combos of the two.
Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
